# Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

> **NCT04905810** · PHASE2 · RECRUITING · sponsor: **Brian Jonas** · enrollment: 20 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Recurrent Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Decitabine
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT04905810
- **Lead sponsor:** Brian Jonas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-02-09
- **Primary completion:** 2025-05-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-05-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04905810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04905810, "Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04905810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*